Poly (ADP-ribose) polymerase (PARP) inhibitor are the first clinically approved drugs designed to exploit the synthetic lethality rate and were first introduced as a cancer targeting strategy in 2005. They have lead to a major change in the treatment of advanced ovarian cancer and altered the natural history of diseases with extreme genetic complexity and defective DNA repair through the homologous recombination (HR) pathway. The novel combination therapies of PARP inhibitors with other anticancer drugs is challenging, and it seems that in the breast related cancer antigens (BRCA) mutation and wild type cancer, the combination of PARP inhibitor and biological agent shows good tolerance and Clinical effectiveness. In particular, different pathways of action of PARP inhibitors combined with anti-angiogenic agents against ovarian cancer may induce greater DNA damage and HR deficiency.